neutec pharma limited
neutec pharma limited Company Information
Company Number
03297187
Next Accounts
Sep 2025
Shareholders
novartis pharmaceuticals uk ltd
Group Structure
View All
Industry
Other human health activities
Registered Address
2nd floor, the westworks buildin, white city place, london, W12 7FQ
Website
www.neutecpharma.comneutec pharma limited Estimated Valuation
Pomanda estimates the enterprise value of NEUTEC PHARMA LIMITED at £0 based on a Turnover of £0 and 0.53x industry multiple (adjusted for size and gross margin).
neutec pharma limited Estimated Valuation
Pomanda estimates the enterprise value of NEUTEC PHARMA LIMITED at £0 based on an EBITDA of £0 and a 4.1x industry multiple (adjusted for size and gross margin).
neutec pharma limited Estimated Valuation
Pomanda estimates the enterprise value of NEUTEC PHARMA LIMITED at £69.5m based on Net Assets of £29.6m and 2.35x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Neutec Pharma Limited Overview
Neutec Pharma Limited is a live company located in london, W12 7FQ with a Companies House number of 03297187. It operates in the other human health activities sector, SIC Code 86900. Founded in December 1996, it's largest shareholder is novartis pharmaceuticals uk ltd with a 100% stake. Neutec Pharma Limited is a mature, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Neutec Pharma Limited Health Check
There is insufficient data available to calculate a health check for Neutec Pharma Limited. Company Health Check FAQs
0 Strong
0 Regular
1 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Neutec Pharma Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Neutec Pharma Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Neutec Pharma Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Neutec Pharma Limited
- - Industry AVG
Employees
with 1 employees, this is below the industry average (19)
- Neutec Pharma Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Neutec Pharma Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Neutec Pharma Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Neutec Pharma Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Neutec Pharma Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Neutec Pharma Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Neutec Pharma Limited
- - Industry AVG
Debt Level
There is insufficient data available for this Key Performance Indicator!
- - Neutec Pharma Limited
- - Industry AVG
NEUTEC PHARMA LIMITED financials
Neutec Pharma Limited's latest turnover from December 2023 is 0 and the company has net assets of £29.6 million. According to their latest financial statements, we estimate that Neutec Pharma Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 3,543,000 | ||||||||||||||
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | 622,000 | ||||||||||||||
| Interest Payable | |||||||||||||||
| Interest Receivable | 147,000 | 147,000 | 147,000 | 146,000 | 146,000 | 144,000 | 1,027,000 | ||||||||
| Pre-Tax Profit | 147,000 | 147,000 | 147,000 | 146,000 | 146,000 | 144,000 | 779,000 | ||||||||
| Tax | -34,000 | -28,000 | -28,000 | -28,000 | -28,000 | -27,000 | 403,000 | ||||||||
| Profit After Tax | 113,000 | 119,000 | 119,000 | 118,000 | 118,000 | 117,000 | 1,182,000 | ||||||||
| Dividends Paid | |||||||||||||||
| Retained Profit | 113,000 | 119,000 | 119,000 | 118,000 | 118,000 | 117,000 | 1,182,000 | ||||||||
| Employee Costs | 1,301,000 | ||||||||||||||
| Number Of Employees | 21 | ||||||||||||||
| EBITDA* | 808,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 1,115,000 | ||||||||||||||
| Intangible Assets | |||||||||||||||
| Investments & Other | |||||||||||||||
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | 1,115,000 | ||||||||||||||
| Stock & work in progress | |||||||||||||||
| Trade Debtors | |||||||||||||||
| Group Debtors | 29,569,000 | 29,456,000 | 29,392,000 | 29,329,000 | 29,183,000 | 29,037,000 | 11,332,000 | ||||||||
| Misc Debtors | 77,000 | ||||||||||||||
| Cash | 390,000 | ||||||||||||||
| misc current assets | |||||||||||||||
| total current assets | 29,569,000 | 29,456,000 | 29,392,000 | 29,329,000 | 29,183,000 | 29,037,000 | 28,375,000 | ||||||||
| total assets | 29,569,000 | 29,456,000 | 29,392,000 | 29,329,000 | 29,183,000 | 29,037,000 | 29,490,000 | ||||||||
| Bank overdraft | |||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 141,000 | ||||||||||||||
| Group/Directors Accounts | |||||||||||||||
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 55,000 | 111,000 | 83,000 | 55,000 | 895,000 | ||||||||||
| total current liabilities | 55,000 | 111,000 | 83,000 | 55,000 | 233,000 | ||||||||||
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | |||||||||||||||
| total long term liabilities | |||||||||||||||
| total liabilities | 55,000 | 111,000 | 83,000 | 55,000 | 233,000 | ||||||||||
| net assets | 29,569,000 | 29,456,000 | 29,337,000 | 29,218,000 | 29,100,000 | 28,982,000 | 29,257,000 | ||||||||
| total shareholders funds | 29,569,000 | 29,456,000 | 29,337,000 | 29,218,000 | 29,100,000 | 28,982,000 | 29,257,000 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 622,000 | ||||||||||||||
| Depreciation | 186,000 | ||||||||||||||
| Amortisation | |||||||||||||||
| Tax | -34,000 | -28,000 | -28,000 | -28,000 | -28,000 | -27,000 | 403,000 | ||||||||
| Stock | |||||||||||||||
| Debtors | 113,000 | 64,000 | 63,000 | 146,000 | 146,000 | 29,037,000 | -27,985,000 | 27,985,000 | |||||||
| Creditors | -141,000 | 141,000 | |||||||||||||
| Accruals and Deferred Income | -55,000 | -56,000 | 28,000 | 28,000 | 55,000 | -895,000 | 895,000 | ||||||||
| Deferred Taxes & Provisions | |||||||||||||||
| Cash flow from operations | -147,000 | -147,000 | -147,000 | -146,000 | -146,000 | -29,009,000 | -25,738,000 | ||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | |||||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | |||||||||||||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | 147,000 | 147,000 | 147,000 | 146,000 | 146,000 | 144,000 | 1,027,000 | ||||||||
| cash flow from financing | 147,000 | 147,000 | 147,000 | 146,000 | 146,000 | 29,009,000 | 29,102,000 | ||||||||
| cash and cash equivalents | |||||||||||||||
| cash | -390,000 | 390,000 | |||||||||||||
| overdraft | |||||||||||||||
| change in cash | -390,000 | 390,000 |
neutec pharma limited Credit Report and Business Information
Neutec Pharma Limited Competitor Analysis
Perform a competitor analysis for neutec pharma limited by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other mature companies, companies in W12 area or any other competitors across 12 key performance metrics.
neutec pharma limited Ownership
NEUTEC PHARMA LIMITED group structure
Neutec Pharma Limited has no subsidiary companies.
Ultimate parent company
NOVARTIS AG
#0001237
2 parents
NEUTEC PHARMA LIMITED
03297187
neutec pharma limited directors
Neutec Pharma Limited currently has 5 directors. The longest serving directors include Mr Edward Fowler (Nov 2010) and Mr Jason Brooks (May 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Edward Fowler | United Kingdom | 49 years | Nov 2010 | - | Director |
| Mr Jason Brooks | United Kingdom | 52 years | May 2019 | - | Director |
| Mr Jason Brooks | United Kingdom | 52 years | May 2019 | - | Director |
| Mr Jason Brooks | United Kingdom | 52 years | May 2019 | - | Director |
| Mr Jason Brooks | United Kingdom | 52 years | May 2019 | - | Director |
P&L
December 2023turnover
0
0%
operating profit
0
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
29.6m
0%
total assets
29.6m
0%
cash
0
0%
net assets
Total assets minus all liabilities
neutec pharma limited company details
company number
03297187
Type
Private limited with Share Capital
industry
86900 - Other human health activities
incorporation date
December 1996
age
29
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
neutec pharma plc (October 2006)
hallco 125 plc (February 1997)
accountant
-
auditor
KPMG LLP
address
2nd floor, the westworks buildin, white city place, london, W12 7FQ
Bank
-
Legal Advisor
-
neutec pharma limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to neutec pharma limited. Currently there are 0 open charges and 1 have been satisfied in the past.
neutec pharma limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for NEUTEC PHARMA LIMITED. This can take several minutes, an email will notify you when this has completed.
neutec pharma limited Companies House Filings - See Documents
| date | description | view/download |
|---|
